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Abstract
Background: HFE-related hereditary haemochromatosis (HH) is a common autosomal recessive disorder with clinical
manifestations ranging from asymptomatic disease to possible life-threatening complications. Cirrhosis, hepatocellular
carcinoma, diabetes mellitus or osteoporosis can develop in HH patients not treated or monitored optimally. The
purpose of this study was to develop key-interventions (KI’s) to measure and improve the quality of care delivered to
patients diagnosed with HH.
Methods: A RAND-Modified Delphi method was used to develop KI’s. In the first round of a scoring form to prioritize
the recommendations extracted from evidence-based guidelines was circulated between experts. The results of this
survey were discussed in a consensus meeting, followed by a final appraisal of the selected recommendations. This
resulted in a list of measurable KI’s.
Results: Initially, 41 key recommendations on screening, diagnosis and treatment/management were extracted from
three existing guidelines on HH (European Association for the Study of the Liver, American Association for the Study of
Liver Diseases and Dutch guideline on HH). Finally, a core set of 24 recommendations resulted in 15 KI’s.
Conclusions: This manuscript presents the results of the process to develop KI’s to measure and improve the quality of
care for patients with HH.
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Background
HFE-related hereditary haemochromatosis (HH) is a com-
mon chronic autosomal recessive disorder, with a genetic
prevalence of 1/200 to 1/400. It has an estimated carrier
frequency of 1/10 in those from Northern European des-
cent. The phenotype results from inappropriate accumula-
tion of iron, resulting in end-organ damage [1]. Symptoms
can be absent, but complications may also be debilitating
or even fatal such as diabetes mellitus, osteoporosis,
cirrhosis or hepatocellular carcinoma [2–4]. Patients with
HH are seen, due to the variety of symptoms, by many
different professionals, ranging from hepatogastroenterol-
ogists, hematologists, rheumatologists, general practi-
tioners to nurses. The varying published criteria for case
definition, referral, diagnosis, interpretation of test results,
follow-up and family screening approaches may lead to
confusion in the diagnosis, treatment and follow-up
process for physicians, patients and their relatives. Almost
20 years after the description of the causal gene defect in
the HFE gene, allowing the definite diagnosis of HH, the
level of understanding of the medical risk associated with
adequate vs. inadequate treatment and follow-up, with
regard to the disease-associated complications described
above, is virtually unchanged. For instance, there is no
clear view on the risk of developing diabetes, once treat-
ment is installed [5], compared to the risk in the general
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population, let alone the risk of developing osteoporosis
or hepatocellular carcinoma. One of the factors hamper-
ing progress in our understanding of the disease-
associated risk, in our opinion, is the lack of well-defined
standards (i.e. key-interventions, KI’s) for screening,
treatment and follow-up of HH. International guidelines
on HH exist [6–9] but, as we demonstrated recently, their
applicability is limited as they fail to describe how long-
term follow-up should be organized and evaluated [10].
To enable treatment evaluation, to support improve-
ment of delivered care and to assist professionals with
the delivery of optimal care to their HH patients, we
developed KI’s for HH. This study is unique, as the KI’s
are formulated, starting from recommendations based
on the integration of three evidence-based guidelines.
Methods
A RAND-modified Delphi method was used to develop
key-interventions (KIs) related to screening, diagnosis,
treatment and follow-up of patients with HH in five
steps, see Fig. 1 [11, 12]. This method combines
evidence-based practice with expert opinion by using a
multidisciplinary panel in the systematic process of
developing KIs [13].
Extraction of recommendations
References to guidelines on HH were searched in the
Medline database as well as the National Guideline
Clearinghouse using following MESH terms: ‘haemo-
chromatosis’ and ‘practice guideline (publication type)’
or ‘practice guidelines as topic’ (June 2013). Only evidence-
based guidelines with clearly defined recommendations
published over the last 10 years were included. If the guide-
line had been updated, the latest version was used. We
included three guidelines from different professional orga-
nizations: European Association for the Study of the Liver
(EASL), American Association for the Study of Liver
Diseases (AASLD) and Netherlands Association of Internal
Medicine (NIV), the Netherlands Society of Clinical Chem-
istry and Laboratory Medicine (NVKC) and Association of
Laboratory Physicians (VAL) (DUTCH). These three guide-
lines on screening, diagnosis and treatment/management of
patients with primary HH were selected because of their
clearly defined recommendations [6–10]. The selected
guidelines describe evidenced-based recommendations,
whether or not in combination with expert opinion
recommendations [10]. One researcher (AV) extracted the
recommendations from the three guidelines. All recom-
mendations were classified into either ‘screening’, ‘diagnosis’
or ‘treatment/management’, together with their Level of
Evidence (LoE), where possible. If a recommendation had a
slightly different phrasing or if contradictory messages in
different guidelines were encountered, this was mentioned
in ‘comments’ (see Additional file 1: Appendix A).
To evaluate these recommendations, a written scoring
form was sent to a multidisciplinary team of experts
who are involved in the routine care of patients with
HH. This multidisciplinary team (n = 17) consisted of
three hepatogastroenterologists, two rheumatologists,
two cardiologists, two endocrinologists, two hematolo-
gists, three general practitioners and three nurses.
Written scoring form
Forty-one recommendations were sent to the multidis-
ciplinary expert team by e-mail (see Additional file 1:
Appendix A). They were asked to score the recommen-
dations on a nine point scale taking into account the
following question: ‘Is performing this recommendation
important for the delivery of high quality of care for
patients with HH?’ (one point for a bad measure (i.e. no
benefit for the patient) and up to nine points for an ex-
cellent measure). The multidisciplinary team was asked
to take into account ‘health gain’ (morbidity, mortality,
quality of life), ‘patient burden’ and ‘side effects’ when
scoring the recommendations. When it was impossible
for a team member to judge the statement, he/she could
mark it as ‘impossible to judge’. Panel members were en-
couraged to add new recommendations or make changes
to the existing recommendations. Subsequently, the team
members were asked to prioritize the three most relevant
recommendations for each domain (screening, diagnosis
and treatment/management). The scoring form was filled
out by 15 of 17 experts (see Additional file 2: Appendix B).
One endocrinologist did not respond despite several
reminders. One endocrinologist only suggested two extra
Fig. 1 Selection of guidelines
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recommendations regarding diabetes mellitus and did not
score the proposed recommendations.
A summary report was drafted, based on the individual
results of the written scoring form to facilitate the consen-
sus meeting. This summary report marked the recom-
mendations as having received a ‘low’, ‘uncertain’ or ‘high’
potential to deliver good quality of care in patients with
HH from the experts. Three selection criteria were taken
into account, i.e. pre-selection, top-3 percentage and
agreement between scorers, which led to a final selection
of recommendations.
Pre-selection was summarized into an overall ranking
score and median rating. Each participant had to score
the top three for screening, diagnosis and treatment/
management. Calculation of this overall rating existed of
ranking a recommendation first, second or third with
three, two and one point(s) respectively. Taking into
account the maximum score (number of panel members
who scored this item multiplied by three), the result was
converted into percentages. This methodology is described
in reference [13].
High potential recommendations were those with a
high overall ranking score (top-3 percentage > 20 %) as
well as a high median score (≥8). If a recommendation
had both a low score on overall ranking (overall ranking
of 1–20 % or < 1 %) and median rating (<8), this recom-
mendation was classified as a recommendation with low
potential. Other combinations were classified as rec-
ommendations with an uncertain potential (median
score < 8 and top-3 percentage > 20 %; overall ranking
of 1–20 % and median score of ≥ 8) (Table 1). A
cutoff for overall rating of 20 % and a median score
of ≥ 8 was associated with good reproducibility and
reliability as well as face validity [13].
Criteria for (dis)agreement
The evaluation of agreement between the members of
the expert panel showed agreement in scoring by a ≥
70 % scoring in the highest tertile (7–9) (Table 2A). If ≥
30 % of the panel members scored in the lowest tertile
(1–3) and ≥ 30 % scored in the highest tertile (7–9)
(Table 2B), there was disagreement. Such an item be-
came a discussion point for the consensus meeting. All
other combinations resulted in no selection (Table 2C).
The items selected for the consensus meeting, were
those with a high potential if pre-selection and agree-
ment were positive. A low potential was given to those
recommendations which were not pre-selected and
showed no agreement or those without agreement and a
questionable pre-selection (no selection). All other com-
binations resulted into recommendations with an uncer-
tain potential (discussion) with regard to delivering high
quality of care for patients with HH (Table 3).
Consensus meeting
A face-to-face consensus meeting was organized to
discuss the recommendations. Consensus was agreed be-
tween a hepatogastroentrologist, a hematologist, a cardi-
ologist, a rheumatologist and a specialized nurse. It took
90 min to discuss the 41 recommendations. An overview
of the ‘high’, ‘low’ and ‘uncertain’ potential of each
recommendation was given to the panel members
(see Additional file 3: Appendix C). Three additional
recommendations completed the list for the panel.
Recommendations with a high potential were in-
cluded. There was discussion about the items with an
uncertain potential and the extra recommendations
for inclusion or rejection. There was also discussion
about rejection in case of ‘low potential’ recommen-
dations. This discussion was moderated by an inde-
pendent researcher (DS) who did not participate in
the scoring of the recommendations.
Final appraisal of recommendations
The final list of selected recommendations was sent to
all scoring panel members after the consensus meeting
(see Additional file 4: Appendix D). All 15 panel mem-
bers agreed with the core set of recommendations.
Development of key-interventions
The recommendations were subsequently translated into
key-interventions for patients with an established diag-
nosis of HH. These key-interventions were formulated
by two researchers (AV and DC).
Results
Three guidelines met our search criteria: 1 European
(EASL), 1 American (AASLD) and 1 guideline from the
Netherlands (Dutch) (Fig. 1) [6–9].
At the start, 41 recommendations were extracted from
the three guidelines (see Additional file 1: Appendix A).
Key recommendations were assigned to three domains:
screening (9), diagnosis (7) and treatment/management
(25) (Fig. 2). Where possible, the level of evidence was
reported (see Additional file 1: Appendix A).
Pre-selection (by priority and median score) and
agreement resulted in the inclusion of 28 and exclusion
of 13 recommendations, after the consensus meeting.
Table 1 Key recommendation classification into categories of
high, uncertain and low potential according to their overall ranking
score and median score
Overall ranking score Median score≥ 8 Median score < 8
Top-3 percentage > 20 % High potential (+) Uncertain (+/-)
1–20 % Uncertain (+/-) Low potential (-)
<1 % Low potential (-) Low potential (-)
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The three suggested additional recommendations were
also excluded: two were related to screening of HH in
patients with diabetes mellitus, the third was related to
age restrictions to start phlebotomies. The panel decided
that a general recommendation about age restriction
could not be given, but that on the contrary there was a
need for an evaluation of each individual case. From the
total of 28 included recommendations, eight were
merged into four recommendations as their content
overlapped. Finally, 15 of the 24 recommendations were
transformed into KI’s (Table 4). Nine initial recommen-
dations were excluded because they could not be trans-
formed into measurable indicators or were related to
screening for HH, while our study aims at patients with
an established diagnosis of HH. For instance: ‘HFE test-
ing should be considered in patients with type 1 diabetes
in case of abnormal iron parameters’ (Table 5).
Screening
‘First-degree relatives of HH patients must be screened’ is
highlighted as the most important recommendation in
the ‘screening’ section and the only one which could be
transferred into a KI. All three guidelines (EASL,
AASLD and Dutch) promote screening of first-degree
relatives in patients with HH [6–8]. Other recommenda-
tions were excluded (i.e. screening of patient popula-
tions, presenting with e.g. chronic hepatitis or other
symptoms possibly related to HH) since they were not
related to HH patients and are therefore outside the
scope of our study.
Treatment/management
The treatment and management section was subdivided
into ‘phlebotomy’, ‘examinations’, ‘general issues’ and
‘diet/lifestyle’.
Phlebotomy
All recommendations regarding phlebotomy were trans-
ferred into KI’s. Two of them were merged into one KI.
There was consensus between the three guidelines, i.e.
‘HH patients with raised ferritin levels must start treat-
ment with (bi)weekly phlebotomy (removing 400–500 ml
Table 2 Examples of agreement and disagreement between panel members
A: Agreement (+: selection), B: Discussion Point (+/-), C: Disagreement (–: no selection)
Table 3 Selection of items after scoring
Preselection Agreement Final label
+ – Discussion
– – No selection
– + Discussion
+ + Selection
+/- + Discussion
+/- – No selection
+/- +/- Discussion
+ +/- Discussion
– +/- No selection
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of blood)’. The AASLD clearly promotes a target level of
serum ferritin (SF) between 50 and 100 μg/L [7]. On the
other hand, the Dutch guideline requires a target SF
level under the upper limit of normal [8]. As important
differences between the different laboratories reporting
transferrin saturation (TS) and SF occur, the expert
panel agreed with targeting a SF level between 50 and
100 μg/L, to have a clear cut-off point. There was con-
sensus between the three guidelines as well as between
the experts, that patients with organ damage should
undergo phlebotomies in case of iron overload.
Examinations
The EASL guideline describes that patients must
undergo examinations (transient elastography ((fibros-
can), a non-invasive liver stiffness measurement (Echo-
sens, France)), liver biopsy) in order to detect liver
damage early [6]. During the consensus meeting, two
recommendations were merged into one, which was
transformed into the following KI ’Screening for liver
fibrosis or cirrhosis in HH patients must be performed
and can be performed using either transient elastogra-
phy or biopsy’.
Fig. 2 Selection of key-interventions
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General issues
In contrast to the Dutch guideline, which requires moni-
toring C282Y homozygotes without iron overload every
3 years, the EASL as well as the AASLD require annual
monitoring [6–8]. Considering that annual monitoring is
easier to organize for the health care providers, the ex-
pert panel decided that patients should monitor their SF
yearly (although this is more costly) and start treatment
when the ferritin level rises above the upper limit of the
reference range.
Immunization against hepatitis A (HAV) and B
(HBV)is an important issue in patients with HH because
patients with a chronic liver disease are at higher risk to
develop complications of HAV and HBV [14]. In
addition, patients with cirrhosis must be immunized
against influenza yearly and pneumococci every 5 years.
All three recommendations are supported by the EASL
and were transformed into a KI.
During the consensus meeting, the recommendation to
screen cirrhotic patients for focal liver lesions by ultrasound
as well as measurement of serum alpha fetoprotein every
6 months, was not challenged and supported by the
European as well as the Dutch guidelines [6–8].
Patients with HH can develop a variety of medical prob-
lems, including liver disease, diabetes mellitus, joint disease,
endocrine deficiencies (hypothyroidism, hypogonadism),
cardiac disease, porphyria cutanea tarda and osteoporosis
[2–4]. Assessment and eventual management of these
problems are necessary in order to prevent patients devel-
oping worse or additional complications. Considering this,
the expert panel agreed that patients should have their fast-
ing glycemia and/or HbA1c checked yearly, to detect
diabetes mellitus early. Furthermore, the following EASL
recommendation: ‘physical and radiological evaluation is
necessary to evaluate possible arthralgia and arthritis’ was
changed during the consensus meeting into ‘HH patients
who have complaints compatible with osteoarthritis, must
undergo physical and radiological evaluation’. All these
recommendations were transformed into KI’s (Table 4).
Diet/lifestyle
In theory, additional iron taken up via the diet or via
supplements can be removed via phlebotomy. In general,
however, most physicians will advise their patients to
avoid extra iron uptake from the diet, by avoiding
Vitamin C supplements taken with meals, as well as the
intake of iron supplements. The expert panel considered
that every person, whatever his/her health status is,
needs a healthy diet. Therefore we only selected the
recommendation that patients at start of treatment must
be advised to avoid the intake of alcohol.
Table 5 Recommendations to screen for HH in other patient
populations
Screening
1. HFE testing must be considered in patients with well-defined
chrondrocalcinosis in case of an otherwise unexplained increase in
ferritin and transferrin saturation.
2. HFE testing must be considered in patients with type 1 or type 2
diabetes in case of abnormal iron parameters.
3. HFE testing should not be performed in patients with unexplained
osteoarthritis.
4. HFE testing should be considered in patients with unexplained
chronic liver disease pre-selected for increased transferrin saturation.
Diagnosis
5. Patients from liver clinics should be screened for transferrin saturation
and serum ferritin.
6. Patients from liver clinics should be offered genetic testing if transferrin
saturation and ferritin are increased.
7. If a patient has suggestive symptoms, physical findings or a suggestive
family history, a combination of TS and ferritin should be measured. If
both are abnormal (TS > 45 % and ferritin above upper limit of normal),
HFE mutation analysis should be performed.
8. HFE testing for the C282Y and H63D polymorphism should be carried
out in all patients with otherwise unexplained increased serum ferritin
and transferrin saturation.
9. In C282Y homozygote patients with increased iron stores, liver biopsy
is no longer necessary to diagnose haemochromatosis.
Table 4 Key-interventions to treat patients with HH
Screening
1. First-degree relatives of HH patients must be screened.
Treatment/management
Phlebotomy
2. HH patients with raised ferritin levels must start treatment with
(bi)weekly phlebotomy (removing 400–500 ml of blood).
3. The ferritin target level for HH patients ‘on treatment’ is between
50–100 μg/L.
4. HH patients without indicators of significant liver disease (AST and/or
ALT elevation), but with elevated ferritin, must also proceed to
phlebotomies.
5. HH patients with advanced liver fibrosis or cirrhosis can safely undergo
phlebotomy and must also be treated.
6. HH patients undergoing phlebotomies must be advised to take
adequate hydration before and after treatment and avoid vigorous
physical activity for 24 h after treatment.
Examinations
7. Screening for liver fibrosis or cirrhosis in HH patients must be performed
and can be performed using either transient elastography or biopsy.
General issues
8. HH patients without evidence of iron overload must be monitored
annually and treated when the ferritin rises above normal.
9. HH patients must be immunized against hepatitis A and B.
10. HH patients with cirrhosis must receive yearly influenza and 5-yearly
pneumococci vaccination.
11. HH patients with cirrhosis must be screened every 6 months for
focal liver lesions (by ultrasound and serum alpha fetoprotein).
12. HH patients must be assessed and managed for complications (liver
disease, diabetes mellitus, joint diseases, endocrine deficiency
(hypothyroidism), cardiac disease, porphyria cutanea tarda and
osteoporosis).
13. Fasting glycemia and/or HbA1c must be measured yearly in HH patients.
14. HH patients who have complaints compatible with osteoarthritis,
must undergo physical and radiological evaluation.
Diet/lifestyle
15. HH patients in the iron depletion phase must avoid the intake of alcohol.
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Recommendations that were not selected
Nine out of 24 recommendations which were highlighted
as recommendations to deliver good quality of care were
not selected to be transformed into KI’s. Four were de-
rived from the screening section of the recommendations.
Secondly, five diagnostic recommendations could not be
transformed in quantifiable KI’s (Table 5). The nine rec-
ommendations that did not qualify as KI’s, were all valid
recommendations but not related to the measurement of
the quality of treatment or management of patients who
are already diagnosed with HH.
Discussion
This is the first study describing the development of 15
guideline-based KI’s, derived from three evidence-based
guidelines on HH, by a multidisciplinary expert panel.
The KI’s relate to screening, diagnosis and treatment/
management of HH. The final list of 15 KI’s provides
professionals with parameters to measure and follow-up
quality of care in patients with HH, thereby preventing
the development of serious, potentially fatal complica-
tions in this patient population.
The uniqueness of this study lies in the fact that we
developed KI’s by starting from three evidence-based
guidelines, and followed by applying a RAND modified
Delphi method to develop consensus. Evidence-based
KI’s are the active ingredients in care pathways (CPs)
[15, 16]. CPs aim to improve patient processes and out-
comes by (re)organizing care processes. The European
Pathway Association defines a CP as “a complex inter-
vention for the mutual decision making and organization
of care for a well-defined group of patients during a
well-defined period” [17]. The integration of CPs in a
well-defined group of patients was already described in
several patient settings, i.e. Chronic Obstructive
Pulmonary Disease, Proximal Femur Fracture, patients
with stroke [18–20]. This resulted in better inter-
professional teamwork, a higher level of organized care
and a lower risk of burnout in the case of CPs in acute
health care teams [19]. By using CPs, the care delivered
to stroke patients resulted in more effective treatment
and better use of organized care [20]. Clinical content of
an evidence-based CP can be created through the eight-
step method developed by Lodewijckx et al. [18]. Our
selected KI’s will indeed be used to create a CP by using
hospital-related indicators,and including patient and
organizational indicators will also be considered.
Earlier research shows that outcomes are influenced
by the composition of the expert panel [21]. The
strength of our study is that 15 independent clinical
experts scored the 41 recommendations. The experts
were selected from six different hospitals (tertiary
university hospitals, as well as regional hospitals), from
primary care and from two universities in Belgium. The
appraisers are active in 7 different medical specialties
(see Additional file 2: Appendix B). The consensus meet-
ing was headed by an independent expert (DS) in HH,
from the Netherlands. A limiting factor of our study is
that only 5 experts participated in the consensus meet-
ing, for logistical reasons and that no patient representa-
tives were involved. Nevertheless, only the opinion of a
general practitioner was absent from the consensus meet-
ing and all 15 appraisers agreed with the final list of 15
recommendations, drafted after the consensus meeting.
The resulting set of KI’s, which is a combination of
evidence and expert opinion, is developed to be applic-
able in different health care settings: hospitals as well as
primary care settings. For this reason, the set of KI’s can
be used by different health care professionals, i.e. physi-
cians (hepatogastroenterologists, hematologists, rheuma-
tologists, general practitioners, …) as well as advanced
nurse practitioners [22].
Although we did not probe for prioritization between
the recommendations, at the consensus meeting, the
most important recommendation is clearly that “patients
with raised ferritin levels should start treatment with (bi)
weekly phlebotomy” (recommendation nr. 2), which is
also highlighted in the questionnaire round (see
Additional file 3: Appendix C) and by the three guide-
lines [6–8]. No recommendation about apheresis in HH
patients is included, since this was not described in the
referring guidelines. The goal of treatment is to prevent
HH patients from developing complications of the dis-
ease and, therefore, patients should be assessed for com-
plications and those need to be managed in case they
are present. A longitudinal follow-up, applying the KIs
we propose here, may in addition finally reveal whether
patients with HH – treated adequately – still have an in-
creased risk to develop diabetes.
As described in Additional file 1: Appendix A, there is
a difference in wording of the recommendations between
the three selected guidelines, but there are no important
contradictions. During the consensus meeting, some rec-
ommendations were merged or adapted in view of the
development of KI’s (Additional file 4: Appendix D).
Limitations to this study are that patient representa-
tives are not included in the expert panel notwithstand-
ing the fact that HH patients in general are able to
assume control of their own care process. We are there-
fore planning further qualitative research on how
patients experience the quality of the delivered care by
face-to-face interviews, questionnaires and focus group
interviews. We are particularly interested in further care
coordination in primary care and self-management by
patients, since integrated patient care is becoming more
and more important [23].
The final list of 15 recommendations forms the basis
for the measurement of the quality of the usual clinical
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care and allows to objectively quantify the effects of ad-
aptations to the care path of the HH patient population.
A practice test to assess the measurability of the KI’s is
planned, as well as a study demonstrating improvement
of outcome, when the KI’s are applied.
Conclusion
HH is a common disorder with potentially life-threatening
complications, if left untreated or not treated properly
before irreversible organ damage occurs. To optimize the
care for HH patients, we developed a set of 15 measurable
clinical KI’s. This set of standardized KI’s now allows us to
measure, adapt and deliver high quality of care for patients
with HH in the hospital setting as well as in primary care.
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